KRAS G12C inhibitor 15

• CAT Number: I018115
• CAS Number: 2349393-21-9
• Molecular Formula: C25H21ClF2N4O3
• Molecular Weight: 498.91
• Purity: ≥95%
• Synonyms: (4R,7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-4,9-dimethyl-5-prop-2-enoyl-2,5,9,12-tetrazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-8-one
• InChI: InChI=1S/C25H21ClF2N4O3/c1-4-19(34)31-11-17-25(35)30(3)16-9-29-23-13(24(16)32(17)10-12(31)2)8-14(26)20(22(23)28)21-15(27)6-5-7-18(21)33/h4-9,12,17,33H,1,10-11H2,2-3H3/t12-,17-/m1/s1
• InChIKey: XDVMVEOFPVCHEL-SJKOYZFVSA-N
• SMILES: CC1CN2C(CN1C(=O)C=C)C(=O)N(C3=C2C4=CC(=C(C(=C4N=C3)F)C5=C(C=CC=C5F)O)Cl)C

KRAS G12C Inhibitor 15(CAT: I018115) is a targeted small molecule inhibitor designed to selectively bind to the KRAS G12C mutant protein, a common oncogenic driver in various cancers, particularly non-small cell lung cancer (NSCLC). This inhibitor works by covalently binding to the cysteine residue in the mutant KRAS protein, locking it in an inactive GDP-bound state, which prevents downstream signaling and inhibits cancer cell proliferation. KRAS G12C Inhibitor 15 represents a significant advancement in the development of precision oncology therapies, offering a promising approach for treating cancers driven by this specific mutation. It is part of ongoing research efforts to improve targeted cancer therapies with high specificity and efficacy.